Comparative monthly and annual cost savings with RHI administered with V-Go. Comparative monthly and annual cost savings with RHI administered with V-Go.

Slides:

Advertisements

Similar presentations

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Advertisements

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 2 of 4.

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Audio-Visual-Oral English for Medical Purpose

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:

Copyright © 2006 American Medical Association. All rights reserved.

VISIT OUR WEBSITE TO SHOP TODAY! VISIT OUR WEBSITE TO SHOP TODAY!

Comparison of cost implication of intermediate acting insulin (insulatard) and long acting insulin (glargine) for one month use to patient. Glargine :

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

Sequential insulin strategies in type 2 diabetes.

Athena Philis-Tsimikas, MD The American Journal of Medicine

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Nat. Rev. Cardiol. doi: /nrcardio

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

by Melanie J Calvert, Richard J McManus, and Nick Freemantle

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Effects of insulin administration in streptozotocin-treated mice.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Distribution of total possible savings (y-axis), showing how much total saving there would be if only those over £x per practice per month (x-axis) were.

Zn2+ and NAD(P)H content in Mafa∆panc and Mafa∆panc;Mafb+/− β-cells.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

T1D is reduced in anti-CD3–treated, CXCL10-deficient RIP-LCMV-GP mice (the numbers in parentheses indicate the number of mice in each group). T1D is reduced.

Effect of empagliflozin on efficacy parameters at week 18.

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Noncontrast computed tomography of patient C. B

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Distribution of daily frequency of BGM

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

Distribution of percent consistent facility aspirin use.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Initiation and adjustment of insulin regimens.

Protocol description (randomized phase).

Cost Analysis of Neonatal Drug Distribution Services at Ministry of Health in Saudi Arabia Yousef Ahmed Alomi, Malika Alhadab, Tahani Alotaibi, Awatif.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is

Twice daily regimen N=45 MDI regimen N=28 P Value

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Change in first-phase insulin response (A) and pancreas triglyceride content (B) in responders and nonresponders at baseline (hatched bars), after VLCD.

Hepatic triglyceride content (A), hepatic insulin resistance index (B), and hepatic VLDL1-triglyceride production (C) in responders and nonresponders at.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

Comparative monthly and annual cost savings with RHI administered with V-Go. Comparative monthly and annual cost savings with RHI administered with V-Go. Costs are based on WAC specific to patient baseline regimen. Cost analysis was based on 11 patients at 6 months, with 1 LOCF. Baseline total cost of insulin therapy was $568 PPPM. RHI refers to the ReliOn brand of U-100 RHI, which is manufactured for Walmart by Novo Nordisk. The cost of concomitant medications used at baseline is not factored into this analysis. Pricing for insulin and other antidiabetic agents was based on Elsevier Gold Standard. ProspectoRx. [Database Online] Available from https://prospectorx.com/aspx. Accessed 2 December 2015. Insulin costs were normalized to 30 days based on prescribed daily dose. David Sutton et al. Clin Diabetes 2016;34:201-205 ©2016 by American Diabetes Association